- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01512017
Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites
January 24, 2012 updated by: Lee's Pharmaceutical Limited
A Clinical Study to Evaluate the Safety and Efficacy on Veloderm (a Crystalline Cellulose Simple Occlusive Dressing) for the Split-thickness Skin Graft Donor Sites in Burn and Plastic Surgery
This study is a multi-center, randomized, open and paralleled positive control study for evaluating the safety and efficacy of Veloderm in treatment of split-thickness skin graft donor sites.
The result implies that Veloerm can do it better than Vaseline gauze in accelerating and promoting wound healing of skin graft donor sites.
The present study have indicated that high permeability of Veloderm dressing to oxygen and water vapor.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The rational oxygen permeability of Veloderm dressing also provides a good environment for wound healing.
Therefore, it can be as a temporary skin substitute in the case of missing epidermis to play a role, in order to provide an ideal environment for wound epithelialization.
As regards safety, 1 adverse reaction occured in test group.
It shows effusion under the dressing mild inflammatory infiltration on the wound edge.
After the dressing was changed and the effusion was drained, the patient was relieved.
As Veloderm dressing itself has no direct anti-inflammatory effects, clinical application as appropriate can plus other anti-infective drugs in accordance with patient conditions.
In conclusion, Veloderm is a safe and effective dressing to accelerate the healing of donor sites in burn and plastic surgery.
Veloderm can be used as a temporary skin substitute in case of damage of skin or loss of superficial epidermal (such as burns, wounds, abrasions, ulcers, sores and auto-graft donor areas).
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18-65 years
- Male or female patients
- Skin lesions or losses by burns, plastic surgery, sores, abrasions, donor graft areas and after debridement of chronic wounds
- The area of skin loss or burn surface is less than 50% of total area of body surface
- Subject undergoing first skin harvest 0.25-0.35mm and donor site having a surface area>100cm2
- Subject who is willing to participate in the trial and to sign the informed consent form.
Exclusion Criteria:
- Area of skin loss or burn surface is larger than 50% of total area of body surface
- Electrical burns or chemical burns
- Burns complicated by combined injury
- Test wound needs drugs that may affect wound healing
- Subject who has a known hypersensitivity to hemycellulose
- Contraindication to the use of semi occlusive dressing
- Pregnant or lactating subject
- Any severe disease which in the Investigator's judgement might interfere with study evaluations or threaten patient's safety
- Subject who has chronic renal disease or renal inadequacy, or serum creatinine is more than twice the upper limit of normal
- Subject who has a definite liver disease, TBil or AST, ALT is more than twice the upper limit of normal
- Subject with active hemorrhoea or shock or visceral injury; Subject who has participated in this clinical study or other clinical studies within 3 months
- Subject with mental impairment limiting the ability to comply with study requirements; Subject undergone chronic treatment with immunosuppressants, antineoplastic drugs and corticosteroids for a long time
- Subject who has not signed the informed consent form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Veloderm
|
A natural biological film of vegetable origin.
It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
Other Names:
|
|
Placebo Comparator: Vaseline
|
External use
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response Criteria
Time Frame: 3 months
|
To observate the efficacy measurements, vital signs, laboratory examinations and adverse events
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation criteria
Time Frame: 6 months
|
To evaluate the time to complete epithilization, effectiveness, presence of exudates, presence of prei-lesional erythema, pain intensity and laboratory examination
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
September 14, 2010
First Submitted That Met QC Criteria
January 13, 2012
First Posted (Estimate)
January 19, 2012
Study Record Updates
Last Update Posted (Estimate)
January 25, 2012
Last Update Submitted That Met QC Criteria
January 24, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZHAOKE-VL2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Split-thickness Skin Graft Donor Sites
-
Brigham and Women's HospitalMedline IndustriesCompletedSplit-thickness Skin Graft Donor Sites
-
Brigham and Women's HospitalWithdrawnBurns | Split-thickness Skin Graft Donor Sites
-
University of Mississippi Medical CenterWithdrawnSplit-thickness Skin Graft Donor SitesUnited States
-
ConvaTec Inc.Bristol-Myers SquibbCompletedSplit-Thickness Donor Sites.United States
-
ULURU Inc.CompletedPartial-thickness Skin Donor SitesUnited States
-
Klinik BogenhausenCompletedReepithelialization of Skin Graft Donor SitesGermany
-
Nantes University HospitalTerminatedWound Healing | Split Thickness Skin GraftFrance
-
PT. Daewoong InfionEquilab InternationalCompletedSkin Graft Scar | Split-Thickness Skin Graft (STSG)Indonesia
-
Birken AGCompletedAccelerating the Epithelialization of Split Thickness Skin GraftGermany
-
Molnlycke Health Care ABCompletedAcute Wound | Donor Site | Split Skin GraftSweden
Clinical Trials on Crystalline cellulose simple occlusive dressing
-
Nuritas LtdReputable HealthCompletedSleep | Healthy Participants | Cortisol | Cognitive Abilities | Wearable TechnologyUnited States
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Assiut UniversityCompleted
-
Dartmouth-Hitchcock Medical CenterCompletedNon-melanoma Skin Cancer
-
University of FloridaKyowa Hakko Bio Co., Ltd.WithdrawnImprovement in Immune Cell Function in Elderly Humans
-
University of FloridaKyowa Hakko Bio Co., Ltd.CompletedImprovement in Immune Cell Function in Elderly HumansUnited States
-
Tigenix S.A.U.CompletedEPIDERMOLYSIS BULLOSASpain
-
Nuritas LtdCompletedMuscle InjuryCanada
-
Nuritas LtdAustralian Catholic University; Baker Heart and Diabetes InstituteRecruitingExercise | Blood Pressure | Vasodilation | Exercise Performance | Safety and Tolerability in Healthy Volunteers | Vascular Function in Healthy VolunteersAustralia